How do tariffs directly impact life sciences supply chain costs?

Tariffs on pharmaceutical raw materials, active pharmaceutical ingredients (APIs), and finished medical devices increase landed costs. For companies importing from tariff-affected geographies, incremental duty costs can range from 5-25% depending on product classification and origin. This is particularly acute for biologics and specialty pharmaceuticals, where supply sources are geographically concentrated.

Why are M&A deals in life sciences becoming riskier from a tariff perspective?

When acquiring or partnering with another life sciences company, tariff exposure becomes a material liability. Freshfields notes that dealmaking must now account for tariff classification disputes, supply chain geographic concentration, and potential tariff reclassifications post-deal. Acquirers must conduct tariff due diligence alongside traditional financial and regulatory review.

What sourcing strategies should life sciences companies adopt to mitigate tariff risk?

Companies should diversify supplier geography to reduce single-jurisdiction tariff exposure, evaluate nearshoring or reshoring of high-value components to tariff-advantaged regions, and implement tariff optimization strategies such as tariff engineering and Free Trade Agreement (FTA) utilization. Additionally, supply chain teams should model tariff scenarios in demand planning and supplier selection processes.

What compliance infrastructure must life sciences companies strengthen?

Companies need robust trade compliance and tariff classification management systems, documentation protocols for country of origin and supplier qualification, and real-time tariff monitoring platforms. Supply chain teams should also establish cross-functional governance linking procurement, legal, and regulatory affairs to ensure tariff implications are integrated into sourcing decisions.

How do tariff risks differ between large and small life sciences companies?

Larger companies with global manufacturing footprints can optimize tariff exposure across multiple jurisdictions and have resources for tariff planning. Smaller companies with concentrated suppliers face disproportionate tariff impact and have fewer mitigation levers. This creates competitive pressure on smaller players to either integrate tariff costs or pursue partnerships and M&A—both of which now carry elevated tariff-related deal risk.

Trade Policy & Tariffs

High Impact

Tariffs Threaten Life Sciences Supply Chains: New Compliance Risks

Aug 22, 2026

Get tomorrow's supply chain signal

Daily supply-chain brief. Free, unsubscribe anytime.

The signal

Freshfields has identified a convergence of tariff policies and trade dynamics that pose emerging risks to life sciences companies engaged in cross-border pharmaceutical and medical device supply chains. The analysis highlights how tariff regimes—particularly those affecting raw materials, active pharmaceutical ingredients (APIs), and finished products—intersect with complex dealmaking activities in M&A and partnerships, creating a multidimensional compliance and operational challenge. For supply chain professionals in the life sciences sector, this represents a structural shift requiring proactive reconfiguration of sourcing strategies, supplier networks, and trade compliance infrastructure.

Companies cannot simply absorb tariff costs; instead, they must reassess supplier geography, consider nearshoring or reshoring of critical manufacturing, and embed tariff scenario planning into supply chain risk management frameworks. The implications extend beyond cost absorption. Life sciences companies face compounded complexity when executing M&A deals or establishing new partnerships—regulatory alignment, tariff classification disputes, and country-of-origin documentation now constitute material deal risks.

Supply chain teams must collaborate with legal, procurement, and trade compliance functions to model tariff exposure across multiple jurisdictions and product categories.

#regulatory-compliance

#import-duties

#dealmaking-risks

#cross-border-trade

#supply-chain-resilience

Frequently Asked Questions

What This Means for Your Supply Chain

Simulation Suggestion

this month

What if tariff rates on imported APIs increase by 25% across key sourcing jurisdictions?

Model the impact of a 25% tariff increase on active pharmaceutical ingredients imported from primary source countries. Simulate the effect on landed costs, product pricing, margin compression, and the potential shift in supply source decisions toward tariff-advantaged jurisdictions or domestic suppliers. Evaluate lead time and service level implications if suppliers must be changed.

Run this scenario

Simulation Suggestion

strategic

What if sourcing must be restructured to prioritize Free Trade Agreement eligible suppliers?

Simulate the operational and cost impact of rebalancing supplier portfolios to maximize Free Trade Agreement (FTA) utilization and minimize tariff exposure. Model changes in supplier lead times, minimum order quantities, pricing, and service level if moving to FTA-eligible suppliers. Evaluate inventory buffer requirements and demand planning adjustments needed to account for potential longer or more variable lead times.

Run this scenario

Simulation Suggestion

this month

What if tariff classification disputes delay product releases by 2-4 weeks?

Simulate the service level and demand fulfillment impact if tariff classification disputes at customs cause 2-4 week delays in product clearance. Model the effect on inventory positioning, safety stock levels, and customer service targets. Evaluate the cost of expedited air freight versus acceptance of service level degradation and lost demand.

Run this scenario

Go deeper:

Supply Chain Digital Twin: The 2026 Guide

How operators model end-to-end supply chains to see how tariffs, supplier shocks, and regulatory changes ripple across cost, service, risk, and time.

Get the daily supply chain briefing

Top stories, Pulse score, and disruption alerts. No spam. Unsubscribe anytime.

The signal

Frequently Asked Questions

What This Means for Your Supply Chain

Related Articles